Meniere's disease treatment may reduce recurrence of low-frequency sudden sensorineural hearing loss

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006639

Enrollment

100

Registered

2021-10-06

Start date

2021-06-28

Completion date

Unknown

Last updated

2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Test group: Menes S tablets (Betahistine), 1 tablet 3 times a day, for 4 months Isobide (Isosorbide), 30ml 3 times a day, 4 months Control: Follow-up without medication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Unilateral hearing loss, tinnitus, and dullness that occurred suddenly within 2 weeks before the start of the initial treatment. - When the airway threshold of the pure tone hearing test is 30dB or higher at 250 or 500 Hz and less than 30dB at 1, 2, or 4 kHz - Patients who have completed initial treatment (steroids)

Exclusion criteria

Exclusion criteria: - When rotational dizziness persists for more than 20 minutes with the onset of auditory symptoms - When the contralateral hearing is 25dB or higher (standard of normal hearing suggested by WHO), the average airway threshold of pure tone audiometry (average threshold of 0.5, 1, 2, 4 kHz) - If there is conductive hearing loss in pure tone audiometry or if there is a lesion in the eardrum and middle ear on otoscopy - If there is a cause that may cause hearing loss within 1 month of onset. (Example: exposure to noise, anticancer drugs, antibiotics) - taking or need to take steroids, betahistine, or diuretics for other diseases

Design outcomes

Primary

Measure	Time frame
recurrence rate	—

Secondary

Measure	Time frame
earfullness;dizziness	—

Countries

Korea, Republic of

Contacts

Public ContactSeong Hoon Bae

Yonsei University Health System, Severance Hospital

bshsap@naver.com+82-2-2228-3611

Outcome results